Investors & Media

Jeff Albers has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. Mr. Albers currently serves as a Venture Partner at Atlas Venture, an early-stage venture capital firm that invests in life sciences startup companies in the U.S. Since 2021, Mr. Albers has served as Chairperson of the Board of Directors of Blueprint Medicines and previously served as our President and Chief Executive Officer from 2014 to 2022, where he led the research-stage company through an initial public offering and evolved it into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Mr. Albers previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a wholly-owned subsidiary of Sanofi), including Vice President of the U.S. Hematology and Oncology business unit. Earlier in his career, Mr. Albers was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. Mr. Albers currently serves as a member of the Audit and Compensation Committees on the Board of Directors of Magenta Therapeutics and as the Chair of the Compensation Committee of the Board of Directors of Kymera Therapeutics. He holds a B.S. from Indiana University and an M.B.A. and J.D. from Georgetown University.